Ferro Corp. (FOE) said that Benjamin Schlater, who has served as Ferro’s Vice President, Corporate Development and Strategy since September 2015, has been named Vice President and Chief Financial Officer, succeeding Jeffrey Rutherford, who stepped down from the position on September 1.
James Barna, Ferro’s Corporate Controller, has been appointed to the additional role of Chief Accounting Officer of the Company.
Lori Saviers, who was Ferro’s Chief Procurement Officer, has been named Vice President, Sourcing and Global Supply Chain. In addition, Sandy Frydryk has been named Director, Corporate Development and Integration.
Rutherford is expected to remain with the Company as an advisor to Schlater through the end of 2016 to ensure a smooth transition of responsibilities.
Schlater joined Ferro in September 2015. He has nearly 20 years of corporate finance experience. His experience includes serving as treasurer and head of corporate development, strategic and financial planning, and risk management at Veyance Technologies, a $2 billion global manufacturing company then owned by The Carlyle Group. Prior to Veyance, he was a managing director at FTI Consulting. Prior to that, he was a manager at PricewaterhouseCoopers in its corporate finance practice.
Source: RTT News
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
